Priming with a Combination of Proangiogenic Growth Factors Enhances Wound Healing in Streptozotocin-Induced Diabetes in Mice

Abstract

Background: Numerous proangiogenic growth factors have been shown to improve impaired wound healing. This study evaluated the effects of subcutaneous pretreatment with a combination of proangiogenic growth factors on wound closure, mechanical properties, vessel density, and morphology. Methods: Thirty-six Balb/c mice with streptozotocin-induced diabetes were divided into 3 groups. A mixture of VEGF (35.0 µg), bFGF (2.5 µg), and PDGF (3.5 µg) was administered subcutaneously 3, 5, and 7 days prior to wounding in the first group, whereas the second group received three doses of 3.5 µg PDGF. Wound sizes were assessed daily and the repaired tissues were harvested 7 days after wound closure. Results: Complete closure (≧95% healing of initial wound area) was reached in all proangiogenic pretreated animals by day 17, whereas the PDGF monotherapy group needed up to 20 days for complete closure. By the time of tissue harvesting on day 24, complete closure was not reached in all control animals. Punch biopsy material revealed 1.6-fold higher vessel densities in the proangiogenic combination-pretreated group than in the controls. Conclusions: Proangiogenic priming revealed several significant effects on diabetic wound healing: faster time to closure, a higher vessel density, and improved functional outcome.

Dual growth factor releasing multi-functional nanofibers for wound healing

“…7C). This is expected due to the fast release of VEGF, which had been proven capable of promoting angiogenesis [19, 42]. After 2 weeks of treatment, full coverage of new epithelium was identified for all samples except the Hydrofera Blue.…”

“…Compared to other wound dressing formations, electrospun nanofibers provide an ECM-like scaffold to support skin regeneration [17, 18]. However, without a fundamental understanding of the biological process and better administration techniques to release biological molecules at essential points of the healing process, optimal wound healing in a fast and finely orchestrated nature still remains a challenge [19, 20]. …”

Priming with proangiogenic growth factors and endothelial progenitor cells improves revascularization in linear diabetic wounds

“…Our own previous experiments have demonstrated the potential therapeutic benefits of priming with proangiogenic factors and cell prior to surgery with a combination of proangiogenic growth factors for wound healing in normoglycemic and diabetic mice (7,8). Priming with a combination of supraphysiological doses of VEGF, fibroblast growth factor (FGF) and PDGF led to more rapid times to closure, higher vessel densities and better functional outcomes (8). In addition to proangiogenic growth factors, endothelial progenitor cells (EPCs) may present a potential pre-treatment option for diabetic wounds.…”

Effects of combination therapy using basic fibroblast growth factor and mature adipocyte-derived dedifferentiated fat (DFAT) cells on skin graft revascularisation

“…Recently, combination therapy of growth factors has been tried. Ackermann et al [26], using a murine diabetes model, demonstrated that faster wound closure and better vascular circulation were obtained with PDGF, VEGF, and bFGF combination therapy than with PDGF monotherapy.…”